Table 3.
Treatment comparisons between the disease groups
| Valid n | HCV (n = 275) | NAFLD (n = 212) | P-value | |
|---|---|---|---|---|
| Radio frequency ablation (RFA) | 487 | 42 (15.4%) | 29 (13.7%) | 0.698 |
| Trans arterial chemo-embolization (TACE) | 487 | 78 (28.4%) | 87 (41.0%) | 0.004* |
| Liver resection | 487 | 8 (2.9%) | 9 (4.2%) | 0.463 |
| Percutaneous ethanol Injection (PEI) | 487 | 9 (3.3%) | 4 (1.9%) | 0.407 |
| Sorafenib therapy | 487 | 15 (5.5%) | 15 (7.1%) | 0.569 |
| Liver transplantation rates over 14 years follow up | 487 | 80 (29.1%) | 21 (9.9%) | <0.001 |
| Liver transplantation by 5 yearsa | 487 | 56.3% | 16.8% | <0.001*a |
Data reported as ‘n (%)’, with P-values from Fisher’s exact test.
aKaplan-Meier estimated rate, censored at death, with P-values from log-rank test.
*
Significant at P < 0.05.